Roche returns rights to SGLT2 inhibitor CSG452 for diabetes to Chugai

6 July 2011

Swiss drug major Roche (ROG: SIX) said yesterday that it will return its development and marketing rights for CSG452, a SGLT2 inhibitor, discovered by its majority owned Japanese subsidiary Chugai Pharmaceuticals (TYO: 4519) and in development for type 2 diabetes.

A license agreement was concluded on January 2007 under which Chugai granted Roche the overseas development and marketing rights for CSG452, and a global Phase II clinical study was conducted as a co-development program. Roche has recently reviewed the priority of its development pipeline, and has decided to return the development and marketing rights of this compound to Chugai.

Chugai will seek new overseas partner

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK